CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics Revenue

In the year 2023, CytomX Therapeutics had annual revenue of $101.21M with 90.38% growth. Revenue in the quarter ending December 31, 2023 was $26.61M with 32.22% year-over-year growth.

• Revenue (ttm): $101.21M
• Revenue Growth: +90.38%
• P/S Ratio: 2.96
• Revenue / Employee: $843,450
• Employees: 120
• Market Cap: 300.01M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	101.21M	48.05M	90.38%
Dec 31, 2022	53.16M	15.85M	42.48%
Dec 31, 2021	37.31M	-31.12M	-45.47%
Dec 31, 2020	68.43M	41.53M	154.36%
Dec 31, 2019	26.90M	-32.60M	-54.79%
Dec 31, 2018	59.50M	-12.12M	-16.92%
Dec 31, 2017	71.62M	56.58M	376.12%
Dec 31, 2016	15.04M	7.33M	95.06%
Dec 31, 2015	7.71M	2.64M	51.90%
Dec 31, 2014	5.08M	4.19M	471.73%
Dec 31, 2013	888.00K	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.